FAKTOR-ZERTIFIKAT - BIOGEN IDEC | Real-time Bid/Ask 10:52:25 2024-05-20 am EDT | ||
| 8.21 EUR / 8.22 EUR | -0.54% |
|
| Current month | -22.37% | ||
| 1 month | -46.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-05-20 | 8.24 | -0.24% |
| 24-05-17 | 8.26 | +0.36% |
| 24-05-16 | 8.23 | +4.44% |
| 24-05-15 | 7.88 | -10.86% |
| 24-05-14 | 8.84 | -3.07% |
Delayed Quote Börse Stuttgart
Last update May 20, 2024 at 05:59 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | J.P. Morgan |
| WKN | JK4G0J |
| ISIN | DE000JK4G0J5 |
| Date issued | 2024-03-22 |
| Strike | 307.5 $ |
| Maturity | Unlimited |
| Parity | 8.78 : 1 |
| Emission price | 10.07 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.19 € |
|---|---|
| Lowest since issue | 7.67 € |
| Spread | 0.01 € |
| Spread % | 0.12% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230.6
USD
Average target price
285.9
USD
Spread / Average Target
+24.01%
- Stock Market
- Certificates
- Certificat
